Profile: Reata Pharmaceuticals Inc (RETA.A)
19 Jun 2019
Reata Pharmaceuticals, Inc., incorporated on March 11, 2002, is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl and omaveloxolone. Bardoxolone methyl and omaveloxolone are members of a class of small molecules called antioxidant inflammation modulators (AIMs). Bardoxolone methyl targets the bioenergetic and inflammatory components of pulmonary hypertension (PH). Omaveloxolone is in clinical development for multiple indications.
Bardoxolone methyl is being studied in a Phase III trial, known as CATALYST, for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial, known as LARIAT, for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of PH. The Company began enrolling patients in its Phase III trial in CTD-PAH. In addition to preclinical models of chronic renal disease, bardoxolone methyl has been studied in over seven studies of patients with chronic kidney disease (CKD) from type II diabetes that enrolled approximately 2,600 patients. Omaveloxolone improves tissue distribution, including blood-brain barrier penetration. Omaveloxolone is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia (FA), mitochondrial myopathies (MM) and metastatic melanoma. Omaveloxolone has been administered orally to patients with FA, MM and solid tumors, and has been administered topically to patients receiving cataract surgery and suffering from radiation dermatitis.
The Company is evaluating omaveloxolone in FA in MOXIe, a randomized, placebo-controlled, double-blind, dose-escalation Phase II trial to evaluate the safety and efficacy of omaveloxolone in over 100 patients with FA at sites in the United States, Europe and Australia. It is evaluating omaveloxolone in MOTOR, a randomized, placebo-controlled, double-blind, dose-escalation Phase II trial to evaluate the safety and efficacy of omaveloxolone in over 100 patients with MM. MOTOR is being conducted at sites in the United States and Europe. The Company has evaluated omaveloxolone in the GUARD trial, a multi-center, randomized, double-masked, vehicle-controlled, parallel group Phase II trial conducted at sites in the United States to evaluate a topical ophthalmic formulation of omaveloxolone in approximately 307 patients undergoing cataract surgery. It is also evaluating omaveloxolone in the REVEAL trial, an open-label, multi-center, dose-escalation Phase Ib/II trial to evaluate the safety, pharmacodynamics and efficacy of omaveloxolone, in combination with existing immunotherapies, in patients with metastatic melanoma at sites in the United States.
The Company has several preclinical programs. The Company is pursuing the preclinical development of orally bioavailable RORgT inhibitors for the treatment of a range of autoimmune and inflammatory conditions. The Company is also pursuing preclinical development of non-AIM neuroprotective heat shock protein 90 (Hsp90) inhibitors, including RTA 901, for the treatment of amyotrophic lateral sclerosis (ALS), diabetic neuropathy, spinocerebellar ataxia and spinal bulbar muscular atrophy.
Reata Pharmaceuticals Inc
2801 Gateway Dr Ste 150
IRVING TX 75063